Introduction: Globally, 600 million people chew areca nut, also known as betel nut, with habitual use being a major risk factor for oral cancer. Taiwan and India have some of the highest age-standardized incidence and mortality rates of oral cancer, underscoring the significant health burden in these countries. Aims: This observational cross-sectional study aims to investigate the betel nut consumption habits in the Taiwanese and Indian populations and assess their awareness of its association with oral cancer. Methodology: An interview was conducted and completed by 516 adults across Taiwan and 989 in India to assess betel nut habits and awareness of oral cancer risks. Results: In Taiwan, 95.2% (n = 491) were aware that betel nut can cause oral cancer versus 51.3% (n = 507) in India. Lifetime prevalence of betel nut use in Taiwan was 19.2% (n = 99) versus 42.6% (n = 421) in India. Only in India was betel nut chewing (OR: 0.6, 95% CI: 0.4–0.8, p < 0.001) associated with decreased awareness of the oral cancer risk linked to betel nut use. Using the population attributable fraction (PAF), an estimated 70.5% (95% CI: 46.0–85.5%) of oral cancer cases in India and 53.7% (95% CI: 42.2–64.1%) in Taiwan are potentially attributable to betel nut use. Conclusions: Betel nut use remains prevalent in India and Taiwan, with lack of awareness posing a greater challenge in India and betel nut use being associated with higher risks of self-reported oral cancer symptoms. Effective intervention requires country-specific strategies to curb usage, improve awareness of associated risks and government strategies to reduce betel nut cultivation and availability.

Background: Sinonasal undifferentiated carcinoma (SNUC) is an extremely rare, high-grade, and aggressive tumor of the sinonasal tract. Due to the rarity of this malignancy, current treatment guidelines are based on small and often/mainly single-center retrospective datasets. In the absence of a universally accepted standard of care for SNUC, treatment approaches vary across countries and institutions, reflecting real-world clinical practice. The primary aim of this study was to describe real-world treatment and outcomes for patients with confirmed SNUC. Methods: This was an international, multi-center, retrospective, observational cohort study that pooled patients into the largest SNUC dataset to date. Fifteen centers were enrolled to contribute data, including seven from Europe, four from the United States, three from the United Kingdom, and one from Canada. In the absence of a universally accepted standard of care for SNUC, treatment approaches varied across countries and institutions, reflecting real-world clinical practice. Patients included were those with histologically confirmed SNUC who were treated between 1997 and 2021. Results: This study yielded 485 patients treated for SNUC. The median age at diagnosis was 55.6 years (IQR: 44.5–67.6), and 63.7% were male. Most cases presented at advanced stages, with 70.8% as T4a or T4b. Overall survival (OS) outcomes were available for 412 patients, with a median follow-up of 26.0 months. The 5- and 10-year OS were 47.2% (95% CI: 40.8–53.3%) and 39.6% (95% CI: 32.5–46.6%), respectively. Advanced age, dichotomized T-stage (T4a/b vs. T1–3), M-stage, and orbital involvement were significant poor prognostic factors on univariable analysis (p’s < 0.01). On multivariable analysis, orbital involvement (HR: 2.73, 95% CI: 1.42–5.27, p = 0.003) and distance metastasis stage (HR: 3.00, 95% CI: 1.25–7.21, p = 0.014) were both independently associated with worse OS. Conclusions: This observational study presents the largest multi-center cohort analysis of SNUC to date, providing new insights into prognostic factors for a rare cancer treated at global centers of excellence. Orbital involvement and the presence of metastases are candidate independent risk factors associated with poorer OS.

Background: Human papillomavirus (HPV)-positive oropharyngeal squamous cell carcinoma (OPSCC) differs from HPV-negative OPSCC in its molecular, biological, and clinical characteristics. We reviewed the literature on radiological differences between HPV-positive and HPV-negative OPSCC across ultrasound, CT, MRI, and PET-CT as this appears to be a critical gap in the literature. Methods: We performed a narrative review of studies reporting imaging findings in OPSCC by HPV status. Two reviewers independently searched PubMed, Ovid MEDLINE, Ovid EMBASE, and the Cochrane Library, from inception to February 2026, supplemented by searching major radiology journals and the grey literature. Eligible English-language studies included patients with OPSCC of known HPV status, assessed at least one imaging modality, and reported imaging findings stratified by HPV status. After title, abstract, and full-text screening, 66 studies were included. Results: HPV(+) OPSCC was more commonly associated with well-defined primary tumours and a higher prevalence of nodal metastases, particularly cystic nodal metastases and extranodal extension. These findings were broadly concordant with reported radiomic signatures. MRI studies suggested lower apparent diffusion coefficient values, while PET-CT studies suggested higher entropy and smaller primary lesions in HPV-positive disease. Conclusions: Selected imaging features may help distinguish HPV(+) from HPV(−) OPSCC, but current evidence remains insufficient for reliable standalone clinical application. Prospective multicentre validation and integration of multimodal imaging, radiomics, and radiogenomics are needed to improve non-invasive HPV stratification and support future precision diagnostics.

Sinonasal cancer treatment confers extensive and diverse sequela, which may persist for months to years after treatment or manifest as late effects. Furthermore, recurrences are common for some subtypes and may occur beyond five years post-treatment of the initial malignancy. Altogether, these can place a substantial physical, psychosocial, and economic burden on the survivor. Due to the rarity of these cancers, there are limited data to comprehensively elucidate the landscape of treatment-related morbidity in the long term. Furthermore, survivors may lack awareness of the entirety of possible adverse effects, which may exacerbate their long-term psychosocial well-being and quality of life, and delay attainment of appropriate care. To enable the development of patient education strategies and provide clinicians with up-to-date, evidence-based information on the long-term and/or late morbidity associated with sinonasal cancer treatment, a comprehensive review was performed. There is a wide range of issues that survivors face, both due to the sinonasal cancer itself and as a result of the treatment, highlighting the need for multidisciplinary survivorship care. Importantly, survivorship care will greatly benefit from patient and public involvement, alongside input from medical, surgical, and allied health professionals, to ensure that all aspects of care are addressed throughout the survivor journey.